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Pulmonary formulationIn the 50 years following the introduction of the ﬁrst dry powder inhaler to the market, several develop-
ments have occurred. Multiple-unit dose and multi-dose devices have been introduced, but ﬁrst generation
capsule inhalers are still widely used for new formulations. Many new particle engineering techniques have
been developed and considerable effort has been put in understanding themechanisms that control particle
interaction and powder dispersion during inhalation. Yet, several misconceptions about optimal inhaler
performance manage to survive in modern literature. It is, for example still widely believed that a ﬂow
rate independent ﬁne particle fraction contributes to an inhalation performance independent therapy,
that dry powder inhalers perform best at 4 kPa (or 60 L/min) and that a high resistance device cannot be
operated correctly by patients with reduced lung function. Nevertheless, there seems to be a great future
for dry powder inhalation. Many new areas of interest for dry powder inhalation are explored and with
the assistance of new techniques like computational ﬂuid dynamics and emerging particle engineering
technologies, this is likely to result in a new generation of inhaler devices and formulations, that will enable
the introduction of new therapies based on inhaled medicines.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Therapeutic drug administration by inhalation covers a period of
more than 4000 years and ﬁnds its origin in India and the Middle East
[1].In the second half of the twentieth century, inhaler technology
rapidly developed along three different pathways. The availability of
electric pumps gave a boost to the development of jet nebulisers,
whereas the evolution of chloroﬂuorocarbon propellants for military
purposes in the interbellum between World War I and II enabled the
development of pressurised metered dose inhalers (pMDIs) for thera-
peutic applications, of which the ﬁrst one (Medihaler®, Riker) reached
themarket in 1956 [1]. Simultaneously, the possibilities for dry powder
dispersion were explored and not much later one of the ﬁrst (capsule
based) dry powder inhalers (DPI: Spinhaler®, Fisons) became commer-
cially available in 1971 [2,3]. In the past three decades all three types of
pulmonary administration devices evolved and diversiﬁed rapidly into a
huge variety of different concepts with speciﬁc pros and cons for a large
number of different inhaled drugs. The development of DPIs was stimu-
lated particularly by the Montreal Protocol (1987) on substances that
deplete the ozone layer [4,5] and in the past decennium there is an in-
creased awareness that DPIs may have the best potential for several
new areas of interest for pulmonary administration [6–10].
The development and use of DPIs have originally been focused on
diseases like asthma and COPD. The pulmonary route for these applica-
tions provides direct access to the site of action and has the advantage of
a rapid onset of action. This reduces the total dose to be given substan-
tially compared to oral administration, for a drug like salbutamol even
by a factor of 10 to 20 [11]. Inhaled corticosteroids (ICS), bronchodila-
tors (beta2-agonists and muscarinic receptor antagonists) or combina-
tions of these drugs are nearly all given in low doses varying from a
few to a few hundred micrograms with an exception for cromolyn
sodium in the Spinhaler®, which is administered in the milligram
range [12]. Several capsule based DPIs followed the Spinhaler®
[13–17] before other single dose compartments were considered
suitable too. A concept with four or eight blisters on a disk [18] was
presented as successor of the capsule based Rotahaler® and only a
few years later followed a concept with 60 blisters on a long strip
[19,20]. With these introductions an extension with multiple unit
dose DPIs was made to the single dose DPIs which increased the
patient's comfort. Roughly in the same decade a ﬁrst multi-dose
DPI (Turbuhaler®, AstraZeneca) was developed [21] which contains
200 doses in a supply chamber. In contrast with pre-ﬁlled capsule and
blister inhalers, such DPIs have a dose measuring mechanism that has
to be operated by the patient. By design, and due to the required safety
measures that prevent double dosing and moisture uptake by the drug
formulation and indicate the number of doses left in the device, multi-
dose DPIs are generally more complex than single dose DPIs. Other ex-
amples of currently marketed multi-dose DPIs for anti-asthma and
COPD drugs are Novolizer® (Meda) [22], Genuair® (Almirall) [23],
Easyhaler® (Orion) [24], Clickhaler® (MSD) [25], Nexthaler® (Chiesi)
[26] and Twisthaler® (MSD) [27].Next to the developments in DPI design and formulation, an in-
creasing interest in new therapeutic areas of interest for dry powder
drug delivery can be observed. Examples are antibiotic therapies
against infectious diseases which start and develop in the lungs
(e.g. in bronchiectasis, tuberculosis (TB) and cystic ﬁbrosis (CF)),
vaccination programmes against viral diseases (e.g. inﬂuenza and
measles), systemically acting drugs that cannot effectively be deliv-
ered via the oral route (e.g. like insulin for diabetic patients or levo-
dopa for Parkinson patients in an off-period) or drugs that need a
rapid onset of action, like fentanyl. The effective local targeting that
is obtained by pulmonary administration allows for a reduction of
the total dose to be given, without decreasing the drug concentrations
at the site of action (e.g. for antibiotics). This reduces the adverse sys-
temic side effects for whichmany antibiotics are notorious. Dry powder
inhalation ismuchmore convenient than classic jet nebulisation for this
application as it reduces the time for administration of a dose consider-
ably [28]. Dry powders are in general also more stable than aqueous
drug solutions and do not require cold chain storage or reconstitution
of powders into solutions for nebulisation. This is particularly of impor-
tance for antibiotic therapies or vaccination programmes in tropical
developing countries where cold chain transport and storage may be
problematic. Vaccination is mostly a once-only administration for
which re-usable nebulisers are not the most appropriate devices [29].
Disposable nebulisers can be used, but their performance for the drug
solution to be administered is often uncertain, whereas they still need
electricity (from the mains or batteries) or pressurised air to be operat-
ed. Disposable DPIs are much easier to use in this respect and addition-
ally DPIs are registered combinations with the drug formulation which
guarantees a better drug delivery to the site of action.
Many of the new areas of interest for pulmonary drug administra-
tion require a change from low dose to high dose drugs for which differ-
ent formulation types are needed than adhesive mixtures. High drug
contentsmay increase the inﬂuence of the physico-chemical drug prop-
erties on the behaviour of the powder formulation during inhalation
and frequently particle engineering techniques are needed to obtain
well dispersible powders. The literature contains abundant formulation
studies for inhaled drugs and vaccines, but surprisingly very little atten-
tion is given to improvement of the inhaler design for these new appli-
cations. Nearly all newly developed formulations in the literature are
optimised for existing DPIs that were developed for the administration
of low dose drugs processed into adhesive mixtures. Therefore, the
greatest challenge for future dry powder inhalation applications may
lie in designing well integrated device-formulation systems that enable
one to achieve a good balance between the three major types of forces
that govern pulmonary drug delivery. Fig. 1 shows this balance. The
interparticulate forces in the powder formulation, the dispersion forces
generated by the inhaler during inhalation and the deposition forces in
the human respiratory tract, together determine the success of the pul-
monary administration. Many newly developed drug formulations or
formulation-device combinations require relatively high ﬂow rates of
60 L/min or more through the inhalers to generate dispersion forces
Fig. 1. Desired balance for optimal DPI therapy between the interparticulate forces in the powder formulation, the dispersion forces generated by the inhaler and the deposition forces in
the respiratory tract during inhalation.
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tion [30]. However, the use of such high ﬂow rates results in a decreased
central andperipheral lung deposition [31].With theuse ofmore effective
inhalers (regarding powder dispersion efﬁciency), not only the ﬂow rate
for effective dispersion can be reduced to increase total lung deposition,
dispersionmay also become less dependent on the interparticulate forces
that govern the powder properties (Fig. 1). Many other challenges for dry
powder inhalation exist and they will be reviewed and discussed in this
manuscript.
2. Demands on performance of DPIs and their formulations
Pulmonary drug administration will only result in an effective and
safe therapy when the inhaler is able to reproducibly deliver a high
ﬁne particle dose to the site of action (receptor, infection, absorption
site) in the respiratory tract. Additionally for an effective therapy,
correct inhaler use and good adherence to the therapy are needed.
The inhaler design and powder formulation determine to a large extent
whether these prerequisites can be met.
2.1. Consistency of delivered dose
Firstly, the dose containing or measuring principle has to deliver a
consistent amount of the formulation to the airstream. This depends
not only on the weighing into the dose cavity or container, but also on
an effective discharge of the compartment during inhalation. For pe-
ripheral deposition the discharge has to be within the ﬁrst 1 to 1.5 L of
inhaled air. This may be impossible for high drug doses in capsules for
which the rate and degree of emptying mostly depends on the ﬂow
properties and size distribution of the powder formulation [12,32].
Emptying of the spinning, vibrating or rotating capsules during inhala-
tion is mostly through small holes or slits in the capsule wall and the
mass ﬂow rate is limited by the number and diameter of the holes.
Therefore, capsule inhalers generally have longer emission times than
DPIs making use of open blisters or dose measuring mechanisms that
go with drug supply containers. For the recently introduced TOBI®
Podhaler (Novartis) two inhalations per capsule are recommended,
and if necessary a third one, to ensure that the entire capsule contents
is released [33]. Dosemeasuringmechanisms combined with drug sup-
ply containers have to prevent that double or incorrect dosing is possi-
ble, and that the patientwill stop using the inhaler when themulti-dose
drug compartment is empty. A good dose counter is neededwhich indi-
cates the number of doses left in the device.When the drug formulation
is hygroscopic, good moisture protection in well sealed compartments
is needed, to prevent the occurrence of capillary forces by liquid ﬁlms
between particles [8]. Moisture may be a risk for the chemical stability
of the product, but it also inﬂuences the dispersibility of the powder, es-
pecially when the drug compartments are subjected to humidity and
temperature changes and the capillary forces progress into solid bridges.2.2. Consistency of delivered ﬁne particle dose
As a next step in the inhalation process the entrained powder mass
from the dose cavity has to be dispersed effectively at the attainable
range of ﬂow rates through the inhaler and inhaler retention has to be
low and preferably highly consistent to ensure consistency of the deliv-
ered dose. The nature and differences in efﬁciency of various types of
dispersion forces, like drag and lift forces from the moving air, shear
forces and impaction forces generated in the inhalers, have been
explained and discussed before as well as how they can be generated
by different dispersion principles [10,34,35]. Not only the efﬁciency of
the dispersion forces, but also the duration of powder exposure to
these forces determines to what extent the drug particles can be re-
dispersed from the formulation. Circulation in whirl or classiﬁer cham-
bers may be extended to generate higher ﬁne particle fractions (FPFs),
but at the same time this will increase the emission time of the drug
too. This requires adequate balancing during development between
these various parameters to obtain an optimised inhaler performance.
Moreover, these variables will also depend to a large extent on the pow-
der properties too.
As the last step in the inhalation process, the generated aerosol has
to be transported by the inhaled air stream into the respiratory tract
and be deposited on the site of action. It is well recognised that trans-
port, losses in the oropharynx plus ﬁrst bifurcations and deposition in
the target area all depend on both the aerodynamic particle size distri-
bution and the ﬂow rate with which the aerosol is inhaled [36–39].
Yet, some persistent misconceptions and false expectations exist in
this respect and they will be discussed hereafter as they are all related
to the inhaler design.2.3. Misconceptions
2.3.1. Regarding the optimal ﬂow rate or pressure drop
One of the most widespread fallacies is that all DPIs perform best
at 4 kPa or 60 L/min [40]. However, various comparative in vitro
evaluation studies have shown that this is incorrect. Fig. 2 compares
the FPFs b5 μm as function of the pressure drop for a number of cur-
rently marketed inhalers, showing that most well designed inhalers
deliver about the same FPF in the order of magnitude of 20 to 30%
of the label claim (which is still low after over 40 years of develop-
ment) at relatively low pressure drops of 2–3 kPa. These pressure
drops correspond with a wide range of different ﬂow rates depend-
ing on the inhaler resistance to air ﬂow. Fig. 2 also shows that DPIs
fall into two different categories: those who deliver approximately
the same FPF at all ﬂow rates and those producing higher FPFs
when the ﬂow rate is increased. This difference in ﬂow rate depen-
dency relates to another essential aspect of DPI performance around
which many misconceptions exist.
Fig. 2. FPFb 5 μmas function of thepressure drop across theDPIs for a number ofmarketed
DPIs. A is for corticosteroid (ICS) monotherapy inhalers or ICS from combination therapy
devices; B is for beta2-agonists and anti-cholinergics.
Fig. 3. Comparison of FPF b 5 μm from 3monotherapy ICS DPIs as function of the pressure
drop across the inhalers (A) and the MMADs of these FPFs (B).
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Too often it is still thought that a ﬂow rate independent FPF guaran-
tees a more consistent therapy than a ﬂow rate dependent FPF [40,41].
However, basic equations to describe particle dynamics, like impaction
parameters, indicate that the chance of particle impaction in the upper
respiratory tract, where the particle velocity is high, increases propor-
tionally with the particle velocity and thus, the ﬂow rate through the
same inhaler [39]. Depositionmodelling studies formonosized particles
show that this increased impaction propensity results in a shift in depo-
sition over the entire airways. However, the shift towards larger airways
for larger particles is most pronounced for the upper respiratory tract
where inertial impaction dominates deposition [42]. These theoretical
effects are conﬁrmed by in vivo deposition studies [31]. The shift in
deposition is the reason why DPIs with a constant FPF output should
not be used at higher pressure drops than the pressure drop at which
the plateau value for FPF is achieved, which for many DPIs is already
at 2 to 3 kPa (Fig. 2). Any further increase in pressure drop will result
in more drug loss in the larger airways, including the oropharynx, and
this will be at the cost of central and peripheral lung deposition. For
DPIs delivering higher FPFs at higher ﬂow rates, the shift in deposition
may (at least partly) be compensated by a higher FPF, or a lower mass
median aerodynamic diameter (MMAD) of the aerosol. This principle
of compensation with a higher and ﬁner aerosol has in vivo been con-
ﬁrmed for the budesonide Novolizer® [43] of which the FPF b 5 μm
and the MMAD of this fraction are compared with those from the
Flixotide® Diskus® and Pulmicort® Turbuhaler® in Fig. 3. Towhich ex-
tent and over which range of ﬂow rates this compensation is obtained
depends on the changes in FPF and in the lung deposition pattern,
both with the ﬂow rate, relative to each other. The challenge for future
DPI developments is to limit the range of attainable ﬂow rates through
the device and to balance changes in FPF with changes in deposition
pattern according to the force balance principle shown in Fig. 1.2.3.3. Regarding the inhaler resistance
Resistance to airﬂow is a further essential property of inhalerswhich
needs serious attention in design and development. DPI resistance is a
direct consequence of its design and inhalers with more powerful dis-
persion principles tend to have higher resistances. To create turbulence
or to generate impaction forces, the DPI needs narrow air passageways,
ﬂow obstructions or swirl, vortex or classiﬁer chambers. These do not
only increase the resistance, but also make dispersion more dependent
on the ﬂow rate. Amisapprehension is that high resistance DPIs require
a high ﬂow rate or considerable inspiratory effort to be operated
correctly, which would be a reason not to prescribe such inhalers for
patients with severe COPD [40,44]. Fig. 2 shows that high pressure
drops and thus, high ﬂow rates through high resistance DPIs, may not
be needed. Medium or medium–high resistance DPIs according to the
deﬁnitions of the ERS/ISAM task force [45], like the Turbuhaler® and
Novolizer®, perform probably best regarding lung deposition in the
range of pressure drops between 2 and 4 kPa. It has been shown that
even severe COPD patients are capable of generating such pressure
drops [46]. It has also been shown that it becomes easier to achieve a
high pressure drop when the resistance is higher and this is indepen-
dent of the disease or severity of the disease. Therefore, the inspiratory
effort is not a good argument to deny patients with inspiratory restric-
tions to use a high resistance DPI and in practice excellent results can
be obtained with high andmedium–high resistance DPIs [47]. A further
major advantage of high resistanceDPIs is that they reduce theﬂow rate
and this favours central and peripheral lung deposition. Not being able
to use a high resistance device effectively may have other reasons, like
the inhalation of a (too) low volume as a result of the relatively low
ﬂow rate through high resistance DPIs in combination with dyspnea.
In this respect there exists a great challenge for future studies in dis-
criminating between what patients (with impaired breathing) consider
less comfortable and what they are unable to perform. A better under-
standing may lead to better future DPI design regarding resistance.
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A recentDPI development is themarketing of amulti-doseDPI deliv-
ering extra ﬁne particles with MMAD b 1.5 μm [26]. The expectation
from this development is that it enables a better targeting of the central
and small airways compared to conventional DPIs. This expectation
is based on the comparison between chloroﬂuorocarbon (CFC) and
hydroﬂuorocarbons (HFA) containing pMDIs with the same drug.
From this comparison it was concluded that much lower doses are
needed from HFA pMDIs compared to CFC pMDIs to achieve the same
clinical effect [48]. The improvement is contributed to themuch smaller
particles delivered by HFA pMDIs, having aMMAD of 1.1–1.5 μmversus
3.5–4.0 μm from the CFC holding pMDIs, which facilitates higher depo-
sition in the peripheral lung from theHFApMDI.However, another even
more substantial difference between both types of pMDIs is their plume
velocity, which (without valved holding chamber) causes approx. 90%
oropharyngeal deposition from CFC containing pMDIs versus 30% from
HFA devices [49]. The corresponding doses delivered to the lung are
10% and 70% and it may be expected that a seven-fold lung dose gives
a better clinical effect in spite of a lower deposition efﬁciency for the
smaller particles (Fig. 4). In Fig. 4, the mass fraction exhaled for mono-
disperse particles as function of the particle diameter is presented
[31]. The trends measured for 1.5; 3 and 6 μm particles (two different
ﬂow rates) are extrapolated to 1 μm particles (red markers) and they
are compared with the settling time needed to fall a distance equal to
the diameter of a respiratory bronchiole (0.43 mm). The fair match be-
tween both relationships seems to indicate that the extrapolated data
points have a realistic value. With this inefﬁcient deposition for small
particles in mind, the expectation that DPIs producing extra ﬁne aero-
sols will give improved clinical effect too compared to conventional
DPIs, may be false considering that not only the particle size distribu-
tion, but also the ﬂow rate with which the aerosol is delivered is impor-
tant. Such ﬁne aerosols contain substantial particle mass fractions
b1 μm for which the deposition efﬁciency by sedimentation is low and
aerosols with MMADs in the range between 2 and 2.5 μm delivered at
a relatively low ﬂow rate from a high resistance DPI are expected to
give similar or even higher lung deposition.
2.4. Inhaler use and adherence to therapy
Nomatter how good the DPI design and its in vitro performance are,
the efﬁcacy of the therapy for which it is used may entirely depend
on the patient's compliance with the instructions and adherence
to the therapy. Robustness, ease of handling and convenience are pre-
requisites for correct inhaler use and different studies have suggested
that considerable differences in the occurrence of incorrect inhaler tech-
nique exist between different inhaler types [50]. Different studies also
have different outcomes however, and the data compared by Lavorini
et al. (2008) [51] show that overall taken (26 studies included)Fig. 4. Comparison of the particle fraction exhaled (for monodisperse particles) and the
time needed for a particle to travel a distance (0.43 mm) equal to the diameter of a
respiratory bronchiole by sedimentation at stationary settling velocity. Exhalation data
are derived from Usmani et al. [31] and extrapolated to 1 μm particles.differences in percentages of patients with incorrect inhaler technique
between various inhalers are relatively small. A major complicating fac-
tor in comparing the outcomes of different studies is the fact that the
criteria for incorrect use were different. Some score lists contained
criteria that are at least arguable, like generating insufﬁcient ﬂow rate
through high resistance inhalers without knowing what ﬂow rate is
really needed for good ﬁne particle dose delivery with these devices.
This explains why error percentages may vary extremely between
studies for the same inhaler, e.g. between 4 and 94% adequate use for
the Turbuhaler® [51]. Some of the errors made have no relation with
the inhaler design, like forgetting to exhale before dose inhalation
(most frequent error), exhaling through the device and keeping no
breath hold following dose inhalation and they can therefore, not be
prevented by designing better devices. Incorrect inhaler technique
may further be inﬂuenced by patient-related determinants, like age,
gender and education level of the patient [52] and instructor [53].
Particularly patients using different devices for their therapy are more
prone to perform incorrect inhalation techniques [50] and this offers
opportunities for improvement of new therapies as against TB, which
involve a large number of different drugs (e.g. antibiotics). If such
drugs become all available in the same inhaler device, the efﬁciency of
the drug administration and adherence to the therapy may be signiﬁ-
cantly better than when different devices are to be used. Also inconve-
nience and hygienic aspects may be causes of poor adherence. DPIs
should be small, preferably silent, have an ergonomic design and pre-
vent severe inhaler pollution or powder waste. Keeping re-usable DPIs
in air tight containers with a desiccant compartment may seem a good
solution for hygroscopic drugs, but could become fatal for good inhaler
performance when patient compliance is insufﬁcient [33]. Compliance
also beneﬁts from good feedback signalling to the patient. Seeing, tast-
ing and/or hearing that the inhaler is operated correctly may contribute
to the patient's conﬁdence in the therapy and this will stimulate adher-
ence and compliance. A further aspect known to inﬂuence adherence is
the dose frequency. Some long acting bronchodilators (LABAs and
LAMAs) need to be taken only once daily. Whether this is really an
advantage can be questioned, because forgetting to take a dose may
have serious consequences for the therapy, much greater than for
drugs that have to be taken twice daily [54]. Dose frequency has no
relation to inhaler or formulation design however, and will therefore
not further be discussed in this manuscript.
3. The technical design of DPIs
Basically, a well designed DPI consists of a number of primary and
secondary functional parts and for each of the primary functional
parts different solutions can be chosen. They are a suitable powder for-
mulation for the drug, a pre-ﬁlled single dose compartment or multi-
dose container with a measuring mechanism for the powder formula-
tion, a powder dispersion principle and a housing for all parts. Second-
ary features can include several ways of signalling to the patient for
correct use regarding correct dose activation and inhalation and for
the number of doses left in the inhaler. They may also be measures for
protection against moisture uptake by the formulation in multi-dose
devices or against exhalation through the inhaler. Good signalling to
the patient is one of the most recent developments in DPI technique
and it was ﬁrst introduced with the marketing of the Novolizer® [55].
3.1. Dry powder inhalation formulations
Micronised drug particles in the microgram range cannot be mea-
sured and administered accurately and they have to be processed into
a suitable, mostly free ﬂowing, formulation for inhalation. The two
basic powder formulations for low dose anti-asthma and COPD drugs
are soft spherical agglomerates and adhesive mixtures (Fig. 5). Soft pel-
lets are more appropriate for high dose drugs (mg-range). Since the
drug content of adhesive mixtures is limited by the drug containing
Fig. 5. Scanning electronmicrographs of an adhesivemixture (left) and soft spherical pellet (right). The adhesivemixture is from the RoleniumElpenhaler; the pellet formulation from the
Pulmicort® Turbuhaler®.
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for low drug doses (μg-range) [56]. Of the currentlymarketed originator
devices, only the Turbuhaler® contains so-called soft (spherical) pellet
formulations [21,57] with or without micronised lactose as ﬁller agent
depending on the dose weight to be measured. Although the pellets
have excellent dispersion behaviour in the Turbuhaler®, their use puts
great demands on the production process and the accuracy of the dose
measuring mechanism in the inhaler. For these reasons, and also be-
cause of a relatively low mechanical stability of the soft pellet formula-
tions [58], nearly all other inhalers for low dose anti-asthma and COPD
drugs make use of adhesive mixtures. In such mixtures, originally re-
ferred to as ordered mixtures, the micronised drugs are mixed with
coarse carrier crystals which act as host particles carrying the drug
particles on their surface [59]. For adhesive mixtures, many variables
existwhichvary from the type and size distribution of the lactose carrier
and the drug content in the mixture to the blending conditions during
preparation of the mixture. All these variables inﬂuence the ﬂow prop-
erties and dispersion performance of the formulation during inhalation
and by that, the (consistency of) delivered dose and ﬁne particle dose.
The state of the art regarding adhesive mixtures, as well as various par-
ticle engineering techniques for high dose drugs, will be discussedmore
in detail in paragraph 4 ‘the technical design of dry powder inhalation
formulations’.3.2. Dose measuring systems
For the dose (measuring) system, different options are possible.
Next to capsules and blisters, other pre-loaded dose systems have
been proposed [13] and a variety of measuring mechanisms is used
in combination with drug reservoir containers in multi-dose inhalers
[21,27,41,60–62]. There may be incompatibilities between the drug
formulation and dose system however, which emphasises the need for
an integrated development. For instance, formulations with lower
mechanical instability (e.g. soft spherical pellets or adhesive mixtures
with high drug content or weakened interaction forces introduced by
the use of so-called force control agents) are preferably not used in
drug containers with an excess of volume, as subjection of the inhaler
to violent movements (e.g. dropping) may break-up the powder in
such containers and deteriorate the ﬂow properties and jeopardize
dose consistency. Coarse carrier size fractions may be less favourable
or unsuitable for capsule inhalers as they cannot pass the perforations
in the capsule wall [12,32]. When moisture sensitive drug formulations
are processed in multi-dose reservoir DPIs good protection against
water uptake from the ambient air is needed [63,64].3.3. Powder dispersion principles
Incompatibilities may also occur between the powder formulation
and the dispersion principle. Many different dispersion principles
seem theoretically possible. Yet, most of the currently marketed in-
halers rely on relatively weak and less efﬁcient drag and lift forces in
turbulent air streams. Such dispersion principles require carrier mate-
rialswith relatively smooth surfaces,which aremostly naturally present
in relatively ﬁne carriers [65] or obtained with carrier particle smooth-
ing techniques [66–68]. They mostly beneﬁt also from certain amounts
of ﬁne lactose particles in the mixture [32,69–71] although inconsis-
tencies in this respect have been reported. Dispersion principles that
generate inertial separation forces are by nature more effective and as
a consequence, their performance depends less on the properties of
themixture [35,72]. Theymay, in contrast with dispersion systems rely-
ing on drag and lift forces, perform even better in combination with
mixtures containing carriers with a relatively high surface rugosity
and carriers which do not contain large quantities of ﬁnes [73]. This
difference in demands for the carrier properties shows that general rec-
ommendations cannot be given and that an optimal carrier product for
inhalation does not exist. Which carrier to use for adhesive mixtures
depends on many factors, including the type of drug, the drug content
in the mixture, the mixing conditions and particularly the dispersion
principle of the inhaler. This again asks for well-designed integrated
formulation-inhaler developments.
3.4. DPIs for high dose drugs
Demands on inhaler design for high dose drugs may be different
from those for low drug dose formulations. Many high dose drugs
(e.g. antibiotics) and also some excipients are highly hygroscopic [74,
75]. They also frequently have poor ﬂow properties and this combina-
tion of properties makes them basically unsuitable for multi-dose DPIs
with dosemeasuring systems. Good compatibility between the powder
formulation and the dispersion principle for high dose drugs is even
more important than for low dose drugs and particle engineering of
the drug is often needed to achieve adequate dispersion. Avoiding the
use of excipients in high dose drug formulations in order to minimise
the powder mass inhaled may also require special technologies to
keep the inhaler retention low, such as the use of sweeper crystals in
circulation chambers or classiﬁers [76]. Not many high dose DPI devel-
opments are known up to now and most of them were reviewed very
recently by Claus et al. [77]. An interesting approach is the use of a
powder containing puck in the Orbital® disposable DPI which holds
high drug doses up to 400 mg [78]. The puck releases the powder
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iﬁces into the de-agglomeration chamber in a number of subsequent
inhalations.
3.5. The use of computational ﬂuid dynamics
The design of new DPIs and studies on the performance of currently
marketed DPIs can be supported by computational ﬂuid dynamics
(CFD) [79–82]. Modelling of the inhaler ﬂow ﬁelds may yield informa-
tion that helps understanding the dispersion behaviour of the devices
and show what effect certain design modiﬁcations have on dispersion
[83,84]. CFD may also teach one how to control the inhaler resistance,
improve circulation inwhirl and classiﬁer chambers and to increase tur-
bulence in dispersion zones [85,86]. By knowing the ﬂow trajectories,
predictions can also be made for particle behaviour and this may even-
tually lead to a better understanding of powder break-up and retention
mechanisms in the inhaler. CFD simulations are expensive, time con-
suming and require considerable computational power, whereas the
precise relationship between ﬂuid and particle dynamics is complex
and still partly uncertain due to several assumptions to be made. This
may limit the use of this technique for modelling of the dispersion
process and there is a great challenge in improving the models to
simulate particle–particle interactions, powder break-up and retention
behaviour. Further developments in the ﬁeld of computational particle
tracking could probably solve a number of these limitations.
3.6. Current state of the art
Currently over 60 different DPI designs can be found in the scientiﬁc
literature and on the internet, however, not even half of them have
reached the market so far and the ones that reached and stayed on the
marked are all passive (breath-operated) devices. This number even ex-
cludes hundreds of concepts in the patent literature and some devicesTable 1
Some noteworthy DPI designs from the past two decades.
Inhaler Company Type
Aeroshot QuantumDesigns Single dose
Air2 Alkermes, now Civitas Capsules
Aspirair® Vectura Single blisters
Breezhaler® Novartis Capsules
Clickhaler® Merck, Mylan Multi-dose
Conix™ DPI 3M Cone shaped dose chamber
Cricket™ MannKind Single dose in cartridge
DirectHaler™ DirectHale Single dose caps
Diskhaler® GSK Multiple unit-dose
Diskus® GSK Multiple unit-dose
Dreamboat MannKind Single dose cartridges
Easyhaler® Orion Multi-dose
Ellipta® GSK Multiple unit-dose
Elpenhaler® Elpen Single duo blisters
Exubera® DPI Pﬁzer Single blisters
Genuair® Almirall Multi-dose
Gyrohaler® Vectura Multiple unit-dose
HandiHaler® Boehringer I Capsules
ISF inhaler® Isf S.P.A. Capsules
Jethaler® Ratiopharm Compressed powder ring with scraper
NEXThaler® Chiesi Multi-dose
Novolizer® Meda Multi-dose
TOBI® Podhaler Novartis Capsules
Skyehaler™ Skyefarma Multi-dose
Spiromax® Teva Multi-dose
Spiros® Dura Multiple unit-dose
Taifun® Leiras Multi-dose
3M™ Taper DPI 3M Multi-dose
TwinCaps® Hovione Capsules
Twincer™ RUG, PureIMS Single or double blisters
Twisthaler® Schering/MSD Multi-dose
Turbuhaler® AstraZeneca Multi-doseprimarily developed for local generic markets in Asian countries. The
switch from branded to much cheaper generic inhalation medication
under the pressure on healthcare budgets is a worldwide trend which
is not limited to localmarkets and it is likely to result in the introduction
of several new devices to themarket in the near future [87]. Surprising-
ly, what seems to become also a trend is the use of relatively old capsule
inhaler designs for new high-performance drug formulations [88–90].
Some devices, like the pulmonary delivery system used for Exubera®
(inhaled insulin), have been commercially available only for a short
period of time [91], whereas other developments, being presented
as highly innovative with great potential, were stopped before they
even reached the market, e.g. Spiros® (Dura) [92]. An overview of
the most noteworthy inhaler designs of the past decades is presented
in Table 1.4. The technical design of dry powder inhalation formulations
Powder formulations for inhalation should contain the drug in the
desired aerodynamic size distribution for deposition in the target area
at the ﬂow rate at which they are inhaled. The formulation has to facil-
itate reproducible dosemeasuring and good emptying of the dose com-
partment during inhalation. Furthermore, the formulation should be
dispersed effectively into the inhaled air stream through the DPI during
inhalation. Dispersion with most inhalers is rather incomplete and the
size distribution of the aerosol may differ quite substantially from the
primary particle size distribution of the drug particles. The functional
demands require good ﬂow properties of the formulation and control
of the interparticulate forces in the powder. To achieve these require-
ments different types of formulations, with and without excipients,
and special particle engineering techniques can be applied. It is the pur-
pose of this paragraph to describe and comment on these formulations
and techniques for which the best choicemay depend on the drug dose,Details
Caffeine inhaler (Dave Edwards)
Renamed by Civitas into ARCUSTM for inhaled (high dose) levodopa
Pressurised air activated dispersion
Modiﬁcation of the ISF inhaler for indacaterol en glycopyrronium
Inhaler for generic formulations
Disposable inhaler with reverse-ﬂow cyclone action
Single-use preloaded inhaler; disposable version of Dreamboat
Single-use inhaler for pulmonary and nasal drug delivery
4 or 8 blisters on a disk
60 blisters on a tape
New inhaler for inhaled TechnosphereTM insulin Afrezza
Inhaler for generic formulations
Successor of Diskus for Breo (ﬂuticason vilanterol combination)
Generic version of GSK's Seretide Diskus
Active insulin inhaler with pressurised air aided dispersion into an aerosol chamber;
withdrawn from the market
Second generation of the Novolizer® for aclidinium and aclidinium-formoterol
Generic inhaler targeting the Diskus market
Successor of the Inhalator Ingelheim
Also known as Aerolizer and Cyclohaler (Teva)
Similar to Ultrahaler (Sanoﬁ-Avensis)
Successor of Pulvinal, contains magnesium stearate for extra ﬁne particle aerosol
of BDP and formoterol
Generic DPI for budesonide, formoterol and salbutamol
Also known as Turbospin (PH&T) and T-326 DPI (Nektar Therapeutics)
Inhaler for generic formulations
Previously referred to as Airmax (Norton Healthcare and Yamanouchi)
Battery driven dispersion (active DPI); development stopped
Generic DPI for budesonide
120 doses on a microstructured carrier tape
Marketed (Japan) for Inavir
Disposable inhaler for high drug doses and vaccines (up to 50 mg in one inhalation)
Asmanex (mometasone furoate) inhaler with hexagonal dispersion channel
The only ICS and bronchodilator inhaler with soft spherical pellets
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all, the type of inhaler used.
4.1. Particle preparation techniques
Different techniques are applied to obtain drug particles in the
desired aerodynamic size range. Micronisation is mostly the standard
for anti-asthma and COPD drugs. This so-called top-down manufactur-
ing process can yield good control of the particle size distribution, but
may have several disadvantages, like the creation of ﬂat surfaces, local
distortions of the crystal lattice (for crystalline materials) and charging
of the particles or particle surfaces which all may affect the ad- and co-
hesiveness of the product [28,93,94]. Alternatively, various bottom-up
techniques are available of which super critical ﬂuid drying (SCF) and
spray drying are mentioned frequently in the literature [95–98]. With
these techniques, not only the size distribution can be controlled, but
also to a certain extent the particle shape and (surface) morphology.
This is of relevance since properties such as particle morphology,
shape, density, (surface) porosity and smoothness are known to inﬂu-
ence the bulk properties such as powder ﬂow and dispersibility [28,
99,100]. SCF has particularly been explored for low dose anti-asthma
and COPD drugs, but super-critical carbon dioxide drying of relatively
high molecular thermo-labile protein based pharmaceuticals is also
possible [101]. For stable, crystalline low dose drugs, spray drying may
be less desirable, because this technique yields mostly particles in the
amorphous state with increased moisture sensitivity and thus, reduced
physical stability. For drugs like tobramycin, or aminoglycosidesmore in
general, which are also highly hygroscopic in their crystalline modiﬁca-
tions, spray drying does not have the disadvantage of reducing the
physical stability of the product however. Spray drying may be either
from solutions or from suspensions and co-spray dryingwith excipients
(e.g. surfactants, lipids, volatile agents or carbohydrates)may result in a
wide range of different particle structures and compositions to control
release kinetics [102–105], increase pulmonary absorption and bio-
availability [106,107] or improve the dispersion performance [28,108].
Several other ways of producing particles for inhalation have been
explored and nearly all are bottom-up techniques. Different particle
crystallisation or modiﬁcation techniques have been described to con-
trol particle shape, modiﬁcation and surface morphology. They include
anti-solvent precipitation using ultrasound [109] or growth retarders
and stabilizers [93,110]. Also the solid-state transformation of crystals
from one modiﬁcation into another [111], controlled spherical agglom-
eration in liquid [112] and conﬁned liquid impinging from jets to
produce elongated mannitol particles [113] have been explored.
Spray-freezedried particlesmostly have excellent dispersion behaviour,
but they are extremely voluminous (due to their high porosity) and
allow only very small drug amounts to bemeasured in single dose com-
partments [114,115]. The technique has been combined with thermal
ink-jet spraying for production of a carrier-free (low dose) salbutamol
sulphate formulation [116]. Like spray-freeze drying, freeze drying is
also a suitable technique to dry highly thermo-labile compounds, but
this technique provides limited control over the particle size distribu-
tion and yields powders with very poor ﬂow properties [117]. In
contrast, micro-moulded PRINT particles (Liquidia Technologies) of
drug or drug blended with excipients can be produced in a narrow
size distribution by compression in micro-moulds with a variety of dif-
ferent shapes. This approach has recently reached the scale of cGMP-
compliant production for preclinical and clinical productions [118].
4.1.1. Adhesive mixtures
Because of the cohesive and adhesive nature of themicron sized par-
ticles and the small quantities in which they are administered for anti-
asthma and COPD drugs, formulation is required into powders that
facilitate reproducible dose measuring. The types of formulations used
for low dose drugs have already been mentioned in the Section ‘The
technical design of DPIs’. Most formulation studies in the literatureregarding dry powder inhalation are about adhesive mixtures, because
this is the most widely used type of formulation for low dose drugs.
These studies aim to understand the complex mechanisms that control
drug distribution over and adherence to the carrier surface and the dis-
persion behaviour during inhalation. They often focus on the inﬂuence
of single variables thereon, like the surface properties of the carrier par-
ticles used [119], the presence of carrier (surface) ﬁnes [120], the carrier
particle shape [121] or the effect of drug concentration in the blend
[122]. So far this has not resulted in a more general understanding of
these mechanisms, partially because several interactions between the
variables andmechanisms exist [73]. Because of the poor understanding
so far, recently a different approach has been presented which focuses
primarily on the processes that occur during the mixing process [123].
These processes, governed by the inertial and frictional mixing forces,
control (1) the size and (2) site distribution of the drug particles on
the carrier surface as well as (3) the degree to which drug particles
are pressed against each other and the carrier surface. The net result
or balance of these three parameters can be explained in terms of size
distributions for the adhesive and separation forces which determine
the drug fraction that can be released from the carrier surface during in-
halation. The primary challenges for such an approach are to develop
and explore new techniques that enable one to measure drug particle
size distribution in the mixture and the spatial distribution of the drug
over the carrier surface as well as to investigate which of the variables
of the starting materials and mixing process inﬂuence these three pa-
rameters most.
4.1.2. Carrier modiﬁcation and dispersion aids in adhesive mixtures
Currently, a wide range of crystalline alpha lactose monohydrate
types and sieve fractions are used as the carrier in inhalation formula-
tions [124]. Because of the poorly controlled surface properties of this
natural product and the batch-to-batch variation, there exists a great
challenge in ﬁnding suitable alternative carrier products [125–128].
Other attempts to improve dispersion of lactose carrier based formula-
tions are passivation of the active carrier sites in a ball mill [129], mod-
ulation of the carrier particle rugosity bywet-smoothing in a high-shear
mixer [130] and reducing the interparticulate bonds between drug and
carrier particles with the use of dispersion, or so-called force control
agents (FCAs) likemagnesium stearate [131–134]. The ﬁrst DPIs contain-
ing such FCAs (NEXThaler®, Chiesi and Breezhaler®, Novartis) have re-
cently reached the market [135,136] and some more are known to be
launched on the short term. In the scientiﬁc literature no references can
be found for the use of magnesium stearate in these two devices howev-
er, and the presence of ﬁnely divided insoluble materials in inhalation
products may raise questions about the long term safety of the patients
considering the great health risks related to ﬁne particle inhalation [137].
4.1.3. Special types of adhesive mixtures
A special application of adhesive mixtures for high drug doses are
the so-called supersaturated orderedmixtures or nucleus agglomerates
[138]. This type of formulation differs from soft spherical pellets in that
the pellets contain large lactose crystals as nuclei (Fig. 6). In practice,
this type of formulation is of lower relevance for inhalation because
such mixtures are mechanically highly unstable and they may exhibit
a very low drug content uniformity [139]. A more promising special
type of carrier based formulations are Technosphere® powders which
are utilised byMannKind Corporation for pulmonary delivery of insulin
[140,141]. Technosphere® technology makes use of self-assembling
crystals of fumaryl diketopiperazine with a high speciﬁc surface area
that are capable of absorbing high amounts of proteins and other sub-
stances for delivery to the deep lung. Also particles with effervescent
activity to obtain an active release mechanism for the drug can be con-
sidered as a special application of carrier based formulations [142]. Soft
spherical pellets are less thoroughly studied and the references to this
type of formulation seem limited to one single study [56] and the patent
literature (e.g. [57]).
Fig. 6. Scanning electron micrograph of a broken nucleus agglomerate (supersaturated
adhesive mixture).
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macrophage uptake
Particle engineering is frequently applied for high dose drugs
(mg-range) which cannot be processed into adhesive mixtures as
the carrier load would simply be too high. To reduce the cohesiveness
of the powders, the number of contact points between the individual
particles as well as the surface area per contact point can be reduced
by preparing particles with a high (surface) porosity and/or a highly
corrugated surface. This improves the ﬂow properties and dispersibility
of the powders, whereas the large powder quantity itself facilitates
sufﬁcient reproducibility of dose measuring. Particle engineering tech-
nologies may also be used for special reasons such as: to obtain particle
growth during inhalation, sustained drug release, avoid clearance by
macrophages or, in contrast, provoke the uptake by macrophages. The
list of examples is almost endless and only a few examples are discussed
for possible consequences and the challenges involved avoiding these
consequences. Some of the techniques used may be very promising,
but some are also harsh and impracticable [143]. One of the earliest re-
ports in this respectwas about the preparation of so-called large porous
particles by a double-emulsion solvent evaporation technique [6,144].
Particles that are aerodynamically within the range from 1 to 5 μm,
but geometrically larger due to a high internal porosity have the advan-
tage of diminished clearance by macrophages in addition to improved
dispersion. This elongates their residence time in the deep lung
which makes them suitable for sustained drug release. Sustained re-
lease can also prevent fast systemic uptake of highly water soluble
drugs or lower the number of doses needed. Such geometrically
large particles can be produced by emulsion solvent evaporation or
spray drying techniques [145,146] and may contain surfactants like
distearoylphosphatidylcholine or biodegradable polymers such as
polylactic or poly(lactic-co-glycolic) acid (PLA and PGLA respectively).
Another application of emulsion based spray drying is PulmoSphere™
technology (Nektar Therapeutics) which has been explored originally
for anti-asthma drugs like cromolyn sodium, salbutamol sulphate and
formoterol fumarate [147], but is currently used for high dose antibi-
otics [88–90]. This technique does not produce large porous particles
(geometric diameter b 5 μm), but particles with an open structure to
improve dispersion behaviour. Different ﬂuorocarbon-in-water emul-
sions (with different volatile agents and surfactants) may be used for
this technique depending on the drug. Co-spray drying with excipients
like leucine may result in corrugated particles with the desired im-
proved dispersion behaviour [100]. The degree of corrugation can be
controlled with the amount of leucine and the enrichment in leucine
at the particle surface was found to slow down the water uptake of hy-
groscopic drugs, like Gentamycin. A special application of small insolu-
ble (PLA or PLGA) particles is targeting of the macrophages [148].
Bacteria like Mycobacterium tuberculosis (Mtb) are known to survive
effectively in alveolar phagocytes like macrophages and dendriticcells. Insoluble particles in a size range that can be taken up by themac-
rophages have to release their antibiotic content and eradicate theMtb
within the phagocytic cell. Finally, also inhalable liposomal particle for-
mulations have been proposed for sustained drug release [149,150].
Sustained release particles may reduce the frequency of dose adminis-
tration and contribute to a more constant therapy, providing that the
drug concentrations needed at the site of actionwill become sufﬁciently
high.
4.1.5. Some disadvantages of new particle preparation techniques
There may be disadvantages related to co-spray drying of high dose
drugs with excipients which all have been described in detail before
[151]. In brief, particles with a high porosity and also substantial
amounts of excipients in the formulation increase the volumeof powder
to be inhaled. This may affect the number of inhalations per dose [88],
which could reﬂect negatively on the adherence to therapy. For some ex-
cipients, like PLA and PLGA, the long term effects are still not completely
known yet. An excess of lactic acid in the lungs may on the long term
have an effect on myoﬁbroblast differentiation [152]. Insoluble biopoly-
mers may also accumulate when the rate of removal by macrophages
or degradation does not keep pace with the rate of administration. The
accumulation of surfactants bears the risk of disturbance of the delicate
balance between tissue tension and the surface tension of the alveolar
lining ﬂuid. Such effects may not be noticeable in healthy volunteers,
but could be a risk in patients with various lung diseases. Therefore, the
aim should be to develop high dose pulmonary drug formulations prefer-
ablywithout excipients and tominimise the total inhaledmass and num-
ber of materials. If the complex particle engineering techniques and
excipients are used only to improve dispersion, it is better to search for
other solutions which are more simple, cheaper, possibly safer and do
not increase the powder volumes and masses to be inhaled. Improved
inhaler technology, particularly focussing on an improved dispersion efﬁ-
ciency, could be one of the solutions. For antibiotics, ﬁnding more potent
drugs, using synergistic drug combinations and improving the targeting
to the site of action are additional challenges. Better targeting of the pe-
ripheral lung has for instance been achieved by making drug formula-
tions hygroscopic which leads to particle growth by moisture sorption
in the highly humid environment of the respiratory tract. This growth,
correspondingwith an increase inmass, speeds up the stationary particle
settling velocity. By delivering such particles in the submicron range to
the lungs, substantial deposition in the oropharynx and upper tract can
be avoided to the beneﬁt of a high deposition fraction in the lower
trachea-bronchial tree [153]. This so-called excipient enhanced growth
(EEG) principle makes use of excipients like sodium chloride andmanni-
tol. Reported drug: excipient mass ratios are 50:50 to 25:75 however,
which seems to make the principle less appropriate for high dose drugs,
but the EEG principle can also be utilised for drugs that are hygroscopic
by nature.
5. Challenges for future developments
5.1. DPI design
Several challenges for the improvement of DPI and formulation de-
sign have already been given throughout this manuscript. One of the
most important goals should be further improvement of the efﬁcacy of
dry powder inhalation. Fig. 7 shows that in spite of a gradual increase
in the total lung deposition over the past decades from less than 10%
to between 20 and 40% for currently marketed inhalers, still less than
half the dose becomes available to the site of action (or site of absorp-
tion). In general, the performance of a DPI system can be improved by
establishing a better balance between the three types of forces shown
in Fig. 1. Most studies in the literature are about understanding and
controlling the factors that determine the interparticulate forces in the
powder (blend). They aim to improve the dispersion of the powder
during inhalation [154–156]. The inhaler design as an important
Fig. 7. Development of total lung deposition from DPIs (at approx. 60 L/min) in the past
45 years.
Data fromradiolabelleddeposition studieswith Spinhaler®and ISF inhaler [24], Turbuhaler®
[43,64,194], Novolizer® [43], TOBI® Podhaler [30] andMedTone, representing Dreamboat
[141].
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studies until quite recently [157,158]. Partly, this interest in device
performance can be contributed to the introduction of new techniques
like CFD [81,82]. However, still most studies focus on studying the per-
formance of existing devices or investigating the effect of small design
modiﬁcations thereon [80,83,84,159] as well as understanding the
mechanisms of powder dispersion [86,160,161]. The design of new in-
haler technology is hardly studied. Peer reviewed publications dealing
with CFD-assisted new DPI developments are still not available al-
though most pharmaceutical companies make use of this technique
by now. With the availability of such new techniques in combination
with an increased understanding of the mechanisms of powder disper-
sion, better integrated device-formulation development becomes possi-
ble. One of the challenges is to design optimally tuned combinations of
the powder formulation and the dispersion principle. In this respect it is
highly regrettable that still many consultancy agents or plastic manu-
facturers continue developing inhaler concepts for the market, initially
not knowing for which types of formulation these concepts will be
used. Part of the newly developed devices [162], or existing devices
used for new powder formulations [28,30] are still low resistance cap-
sule based DPIs. This has the disadvantage that powder properties
need to be optimised with respect to both emptying of the capsules
and good dispersion. If the drug formulation is an adhesive mixture,
the carrier material providing best ﬂow properties for discharge of the
capsulesmay not always be the ﬁrst choice from a dispersion viewpoint
however. Moreover, the low airﬂow resistance of these capsule based
DPIs will lead to very high ﬂow rates which is at the cost of central
and peripheral lung deposition (Fig. 1). Therefore, new developments
should aim at limiting the ﬂow rate to b50 L/min at 4 kPa. With the
aid of CFD, this may not be too difﬁcult.
5.2. Dry powder formulations
On the formulation site, several challenges still remain in spite of
many years of effort put in the understanding ofmechanisms of powder
cohesion and dispersion. For adhesivemixtures some relevant variables,
like moisture content or roughness have extensively been described,
but there is insufﬁcient knowledge of the mixture properties and the
processes occurring during the mixing process that affect the ﬁnal
performance of the mixture. The extent to which particles de- and re-
agglomerate and distribute over the carrier surface and to which the
interparticulate forces are increased by inertial and frictional forces
during blending are difﬁcult to measure and require the introduction
of new techniques. For high drug dose formulations the challenges are
not somuch related to getting a better understanding of thepowder dis-
persion properties, because the particle engineering techniques that canbe applied to improve dispersion are well known. However, the low
density particles obtained with these techniques also increase the
volume of the powder to be inhaled, or, when substantial amounts of
excipients are involved, also the powder mass to be administered may
become too large. This increases the number of inhalations for a single
dose [33] which is likely to inﬂuence the adherence to the therapy
negatively. Besides, the long term effect of some of the excipients used
is still uncertain [151]. Using less complex powder formulations and
manufacturing techniques will also reduce production costs and make
large scale antibiotic therapies and vaccination programmes in develop-
ing countries more feasible. In the light of the rapid global spread of
multidrug-resistant and extensively drug-resistant TB and the risk of
new outbreaks of bird ﬂu and SARS, the challenge of making cheap,
but effective inhaler technology for large scale antibiotic or antiviral
therapies and vaccination programmes could well be the major
challenges for the near future. Good dispersion of high dose drug for-
mulations (particularly of the antibiotics) with minimum excipient
content may require adaptation of the inhaler design to the physico-
chemical product properties, which again emphasises the need for inte-
grated device-formulation development. Finally, total dose reduction
can also be obtained by developing more potent drugs (e.g. antibiotics)
or by using synergistic drug combinations. Only a few synergistic
combinations have been reported so far [163,164] and there is a great
challenge in ﬁnding more and developing dry powder inhalation sys-
tems for these combinations.
5.3. Pulmonary vaccination
The pulmonary administration of vaccines in large scale programmes
may raise special challenges [29]. Vaccination is a once-only administra-
tion and if the vaccine delivery to the respiratory tract fails, there will be
no, or insufﬁcient protection. Because of the once-only aspect, disposable
inhalers are preferred for this application, but it may be possible to use
add-on devices with measuring equipment to record the entire inhala-
tion manoeuvre. Monitoring of the inspiratory performance will give a
good feedback to the health care professional and make sure whether
sufﬁcient protection is obtained or not, particularly if robust inhalers
are used that perform well over a wide range of inspiratory efforts. A
preference for disposable inhalers may also have other reasons, like the
administration of hygroscopic formulations and pulmonary antibiotic
administration for which bacterial resistance building in the device
could be a risk. The number of disposable inhalers known in the public
domain is still low however, whereas most of them are still in the devel-
opment phase [165]. For the application of large scale vaccination there
may be a future need for cheap but effective disposable DPIs with robust
performance which can be connected to re-usable monitoring devices.
5.4. Special patient groups
The growing awareness that special inhalers may be needed for
special patient groups like small children and the elderly has not result-
ed in the design of more appropriate devices for these groups yet. Most
currently marketed DPIs are registered for children of six years and
older due to a lack of clinical data for younger children. It has never
been investigated systematically whether some of the children under
six can use these DPIs too, or whether all children of six and more are
indeed capable of understanding the instructions for use and have the
ability to inhale correctly. Studies on dry powder inhalation in children
so far focused either on how they operate speciﬁc DPIs [166–171], or on
single inspiratory parameters like peak ﬂow rate [172,173], and how
these parameters are affected by the airﬂow resistance of the inhaler
[174–177]. One of the greatest challenges for DPIs to be used by small
children will be the delivery of the total dose in their much smaller
inhaled volumes compared to adults [178]. Repeated inhalation of the
same dose may be a solution for this problem, but this should not lead
to exhalation through the device in between the inhalations. The
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They may have reduced inspiratory power and inadequate understand-
ing of how to use an inhaler correctly and they often suffer from insuf-
ﬁcient manual dexterity and hand strength [179]. Therefore, special
DPI designs for small children, which are easy to operate, deliver the
dose in lower inhaled volumes and produce appropriate aerosols at
lower ﬂow rates could also be suitable for use by elderly patients.
5.5. Target sites for inhaled drugs
The site of action may be different for different types of drugs. For
anti-asthma and COPD drugs this depends on the distribution of speciﬁc
receptors for the drug [180,181], the site of inﬂammation [182,183] or
the presence of smooth muscle. Drugs administered via the pulmonary
route for systemic action are mostly best (or exclusively) absorbed in
the peripheral part of the lung and they have to be deposited in the
most distal airways or even the alveoli [184]. For antibiotics against bac-
teria that are present in the entire lung, an equal drug concentration in
the entire lung is desired. Underdosing part of the lungs with antibiotics
may result in obtaining insufﬁcient drug concentrations to reach their
minimum inhibitory concentrations for the organisms to be eradicated
and this has the risk of bacterial resistance building in these regions.
Most studies with currently marketed DPIs show that very roughly
one third of the total lung dose is deposited in the upper airways, one
third in the central airways and one third in the peripheral lung [43,
185,186]. This, in combinationwith the exponentially increasing surface
area of the airways from the trachea to the alveoli, results in drug con-
centration differences between the most extreme generations by more
than a factor 100 [151,187]. Therefore, one of the greatest challenges
for future DPI developments is to increase the peripheral deposition
for these applications. A good approach for that could possibly be the
already discussed excipient enhanced growth by moisture absorption
of aerosol particles to increase their stationary settling velocity [153].
5.6. Patient preference
One aspect of inhaler design that has not been given attention in this
review is patient preference for resistance and type of device. Many
studies on the aspect of patient preference and acceptance are known,
mostly performed in a comparative study between two or more differ-
ent devices [188–191]. Unfortunately, different studies with the same
inhalers produce inverse orders for preference. Like the studies on
critical errors made during inhalation performance, this is mainly due
to differences in questioning and rating of aspects like convenience of
use, signalling to the patient, resistance and appearance. In contrast
with critical error scores, preference scores may also be inﬂuenced by
other factors, such as loyalty to the country in which the inhaler is pro-
duced or to the manufacturer of the DPI. Therefore, inhaler preference,
although highly relevant to patient's adherence [192,193], is difﬁcult
to measure in an objective way and not very useful as a starting point
for inhaler design.
6. Conclusions
Currently most studies on the development of new systems for dry
powder inhalation focus on the drug formulation. Mechanisms of
particle interaction, development of special formulations and particle
engineering techniques to control these interactions aim to improve
dispersion from the formulation side. Relatively little research effort is
put in designing new devices with improved performance on aspects
such as powder dispersion or inhaler resistance. Recent device studies
that can be found in the literature investigate the operating principle
of existing DPIs with CFD simulations, or the effect of design modiﬁca-
tions on the performance of these inhalers.
There is an increasing awareness that good adherence to the therapy
may be just as important as good inhaler performance. This results inthe development of secondary design features meant to give an ade-
quate feedback to the patient on correct inhaler use. Considering that
many future areas of interest for pulmonary drug administration
may be found in antibiotic and antiviral therapy and in vaccination
programmes for developing countries, the take home message for
these applications should be to keep new developments simple and
cheap yet effective and reliable. Well integrated formulation-device
developments may be the key approach to achieve this goal. The
greatest challenges in this respect are to obtain a high robustness
and patient and inhalation ﬂow independent performance, which is
best realised with inhalers that have a ﬂow rate dependent genera-
tion of the FPF, and improved targeting to the site of action or site
of absorption.References
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